Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387463 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2AMAPK1ALDH1A1GAA | |
| SCHEMBL2386588 | 0.83 | HIF1A (0.46) | KMT2AALDH1A1GAAMAPTHIF1A | |
| SCHEMBL1014491 | 0.79 | HIF1A (0.61) | SMN1; SMN2KMT2AMAPK1HIF1AEPAS1 | |
| SCHEMBL2387281 | 0.75 | FAAH (0.51) | ALDH1A1TSHRHRH3 | |
| SCHEMBL2389749 | 0.75 | HIF1A (0.43) | SMN1; SMN2KMT2AALDH1A1GAAMAPT | |
| SCHEMBL2386050 | 0.74 | HSD17B10 (0.46) | SMN1; SMN2KMT2AALDH1A1GAAMAPT | |
| SCHEMBL2387287 | 0.74 | MAPT (0.43) | SMN1; SMN2KMT2AALDH1A1MAPTHIF1A | |
| SCHEMBL2387289 | 0.74 | HIF1A (0.43) | SMN1; SMN2KMT2AALDH1A1GAAMAPT | |
| SCHEMBL27761805 | 0.72 | HRH3 (0.56) | SMN1; SMN2KMT2AMAPK1ALDH1A1GAA | |
| SCHEMBL25062318 | 0.72 | HTT (0.63) | SMN1; SMN2KMT2AMAPK1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2544679-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2544679-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-9434707-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434707-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434707-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9102643-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2011112828-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | PDE10A, PDE9A, PDE7A | SMN1; SMN2 527/4885KMT2A 2449/4885MAPK1 3742/4885 |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | SMN1; SMN2 527/4885KMT2A 2449/4885MAPK1 3742/4885 |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | SMN1; SMN2 527/4885KMT2A 2449/4885MAPK1 3742/4885 |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | SMN1; SMN2 527/4885KMT2A 2449/4885MAPK1 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.